KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Non-Current Liabilities (2016 - 2025)

NovoCure (NVCR) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $240.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 93.73% to $240.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $240.6 million through Dec 2025, up 93.73% year-over-year, with the annual reading at $240.6 million for FY2025, 93.73% up from the prior year.
  • Total Non-Current Liabilities hit $240.6 million in Q4 2025 for NovoCure, down from $243.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $681.2 million in Q2 2024 to a low of $124.2 million in Q4 2024.
  • Historically, Total Non-Current Liabilities has averaged $469.2 million across 5 years, with a median of $586.0 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 1932.01% in 2021 and later tumbled 79.45% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $586.4 million in 2021, then increased by 0.9% to $591.7 million in 2022, then increased by 2.17% to $604.5 million in 2023, then crashed by 79.45% to $124.2 million in 2024, then skyrocketed by 93.73% to $240.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for NVCR at $240.6 million in Q4 2025, $243.9 million in Q3 2025, and $146.8 million in Q2 2025.